Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- EGTX.ST
- Price
- 3.67
- Stock movement down
- -0.10 (-2.65%)
- Company name
- Egetis Therapeutics AB (publ)
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.32B
- Ent value
- 1.45B
- Price/Sales
- 19.39
- Price/Book
- 4.14
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -6.09%
- 1 year return
- -41.56%
- 3 year return
- -14.64%
- 5 year return
- -10.26%
- 10 year return
- -19.60%
Last updated: 2025-04-15
DIVIDENDS
EGTX.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 19.39 |
| Price to Book | 4.14 |
| EV to Sales | 21.29 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 359.24M |
| EPS (TTM) | -1.08 |
| FCF per share (TTM) | -0.73 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 68.00M |
| Gross profit (TTM) | -3.60M |
| Operating income (TTM) | -306.10M |
| Net income (TTM) | -319.40M |
| EPS (TTM) | -1.08 |
| EPS (1y forward) | -0.13 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -5.29% |
| Operating margin (TTM) | -450.15% |
| Profit margin (TTM) | -469.71% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 129.90M |
| Net receivables | 0.00 |
| Total current assets | 164.40M |
| Goodwill | 0.00 |
| Intangible assets | 408.30M |
| Property, plant and equipment | 0.00 |
| Total assets | 577.50M |
| Accounts payable | 19.60M |
| Short/Current long term debt | 111.20M |
| Total current liabilities | 167.00M |
| Total liabilities | 258.90M |
| Shareholder's equity | 318.60M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -216.00M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -216.00M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -100.25% |
| Return on Assets | -55.31% |
| Return on Invested Capital | -92.47% |
| Cash Return on Invested Capital | -62.54% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 3.77 |
| Daily high | 3.88 |
| Daily low | 3.61 |
| Daily Volume | 359K |
| All-time high | 57.90 |
| 1y analyst estimate | 11.00 |
| Beta | 1.43 |
| EPS (TTM) | -1.08 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 6 May 2025 |
Downside potential
Loading...
Downside potential data
| EGTX.ST | S&P500 | |
| Current price drop from All-time high | -93.66% | -12.04% |
| Highest price drop | -94.81% | -56.47% |
| Date of highest drop | 15 Jun 2022 | 9 Mar 2009 |
| Avg drop from high | -62.04% | -11.07% |
| Avg time to new high | 114 days | 12 days |
| Max time to new high | 2332 days | 1805 days |
COMPANY DETAILS
Marketcap
1.32B
Marketcap category
Small-cap
Description
Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a highly debilitating rare disease with no available treatment. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.
Employees
28
Website
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Despite a drop in revenue, Egetis Therapeutics AB (FRA:P0F) strengthens its market position with key approvals and financial maneuvers.
February 27, 2025
STOCKHOLM, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (Nasdaq Stockholm: EGTX), an innovative pharmaceutical company specializing in late-stage develop...
February 20, 2025
As global markets navigate through mixed economic signals, Sweden's market remains a focal point for investors looking for growth opportunities. This context sets the stage to explore three Swedish gr...
June 11, 2024
As global markets experience mixed signals with regions showing varied economic data, Sweden's market remains a point of interest for investors looking for growth opportunities. In this environment, c...
June 10, 2024